Morgan Stanley Downgrades Aardvark Therapeutics to Underweight, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 93.6%

Neg 93.6% Neu 0% Pos 0%

Morgan Stanley analyst Michael Ulz downgrades Aardvark Therapeutics (NASDAQ:AARD) from Equal-Weight to Underweight and lowers the price target from $7 to $3.